Less Frequent Dosing With MS Drug Safe With No Loss of Effic

Patients with MS stable on natalizumab administered every 4 weeks may be able to safely switch to every-6-weeks dosing with no clinically meaningful loss of efficacy.

Related Keywords

Germany , Bochum , Nordrhein Westfalen , Salt Lake City , Utah , United States , John Foley , Kerstin Hellwig , Commitment To Health , Department Of Neurology , European Medicines Agency , Rocky Mountain , Medscape Medical News , Tysabri Outreach , Unified Commitment , Product Characteristics , Catholic Clinic Bochum , Multiple Sclerosis Ms , Multiple Sclerosis , Us , Progressive Multifocal Leukodystrophy , Progressive Multifocal Leukoencephalopathy , Multiple Sclerosis Relapse , S Relapse , Elapse Of Multiple Sclerosis , Elapse Of Ms , Relapsing Remitting Multiple Sclerosis , Arms , Ultiple Sclerosis Relapsing Remitting , Multiple Sclerosis Treatment , Als Treatment , Reatment Of Multiple Sclerosis , Reatment Of Ms , Magnet ,